Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: tazarotene

« Back to Dashboard
Tazarotene is the generic ingredient in three branded drugs marketed by Stiefel Labs Inc and Allergan, and is included in three NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has twenty-two patent family members in thirteen countries.

There are seven drug master file entries for tazarotene. Three suppliers are listed for this compound.

Summary for Generic Name: tazarotene

Tradenames:3
Patents:1
Applicants:2
NDAs:3
Drug Master File Entries: see list7
Suppliers / Packaging: see list18
Therapeutic Class:Dermatological Agents
Formulation / Manufacturing:see details

Pharmacology for Ingredient: tazarotene

Ingredient-typeRetinoids
Drug ClassRetinoid

Clinical Trials for: tazarotene

A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne Vulgaris
Status: Completed Condition: Acne Vulgaris

Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis
Status: Recruiting Condition: Plaque Psoriasis

Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris
Status: Completed Condition: Acne Vulgaris

A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers
Status: Completed Condition: Acne Vulgaris

A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris
Status: Completed Condition: Acne Vulgaris

Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails
Status: Completed Condition: Brittle Nails

Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris
Status: Recruiting Condition: Acne Vulgaris

Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne
Status: Completed Condition: Acne Vulgaris

A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.
Status: Completed Condition: Acne Vulgaris

Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study
Status: Recruiting Condition: Cutaneous T-Cell Lymphoma

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
TAZORAC
tazarotene
GEL;TOPICAL020600-001Jun 13, 1997RXYes<disabled><disabled>
Stiefel Labs Inc
FABIOR
tazarotene
AEROSOL, FOAM;TOPICAL202428-001May 11, 2012RXYes8,808,716<disabled>Y<disabled>
Allergan
AVAGE
tazarotene
CREAM;TOPICAL021184-003Sep 30, 2002RXYes<disabled><disabled>
Allergan
TAZORAC
tazarotene
CREAM;TOPICAL021184-002Sep 29, 2000RXYes<disabled><disabled>
Allergan
TAZORAC
tazarotene
CREAM;TOPICAL021184-001Sep 29, 2000RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: tazarotene

Country Document Number Publication Date
European Patent Office2521584Nov 14, 2012
Canada2784041Jul 14, 2011
European Patent Office2400951Aug 15, 2012
Australia2010217190Sep 22, 2011
Japan2012518662Aug 16, 2012
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc